Biological Anti-Infective Medicines, LLC, located in Bethesda, MD, is a biotechnology company specializing in the development of humanized monoclonal antibodies to treat Acinetobacter infections, a highly antibiotic-resistant pathogen. With a focus on addressing the growing threat of drug resistance, the company has received substantial funding from the Department of Health and Human Services National Institutes of Health to advance their innovative research and development efforts.
As a leader in the field, Biological Anti-Infective Medicines, LLC is dedicated to combating the spread of Acinetobacter baumannii, a major concern in intensive care units across the United States and globally. Through their cutting-edge technology and scientific expertise, the company aims to provide effective solutions to this urgent public health issue.
Generated from the website